Agree with manukes, I love this Co too! A quick review of the OSL Institutional Presentation reveals some good upside inflection points coming to support the recent interest and increased volumes… Positives I see IMHO are… ? Medical devices are far cheaper and quicker to gain FDA approval ? Plenty of cash in the tin at almost $14m ? US FDA Gap analysis and “major” US hospital deal almost signed off ? Study design had loads of input from different sectors to design it properly, efficiently and in getting success ? CEO Frazer’s track record of 5 / 5 (100%) in FDA approval – brother of Gardasil and Australian of the Year Ian Frazer ? Management ownership of ~22% ? Pancreatic cancer market underserviced, less competition ? Proven results in previous studies, pain reduction – side benefit ? Q1 and Q2 2014 IDE, CE and TGA submissions (news flow should continue next year) ? Global registration study and interim analysis throughout 2014 All looks good, motivated management, great early results in previous trials, gun scientists aboard. Could be the next great Aussie bio story IMHO. I’m very long and confident!!!
OSL Price at posting:
12.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)